Navigation Links
Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease in the European Union
Date:3/7/2013

OSAKA, Japan, March 7, 2013 /PRNewswire/ --

Takeda Pharmaceutical Company Limited ("Takeda") today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), the two most common types of inflammatory bowel disease (IBD). If approved, vedolizumab would be the first and only gut-selective biologic agent for UC and CD on the market.

"Ulcerative colitis and Crohn's disease are chronic debilitating diseases with important unmet medical needs, often affecting young people in the prime of their lives," said Asit Parikh , M.D., Ph.D., vice president, general medicine, Takeda. "We are encouraged by the findings of GEMINI, the vedolizumab Phase 3 clinical development program, which studied approximately 3,000 patients in nearly 40 countries, making it the largest IBD clinical trial program conducted to date."

Nearly four million people worldwide are affected by IBD, with UC affecting more than 500,000 people and CD affecting approximately 230,000 people in the EU.Crohn's disease and ulcerative colitis are chronic diseases that cause inflammation of the lining of the digestive tract. Inflammation caused by CD can involve varying areas of the digestive tract, while UC impacts the colon only.CD and UC can be both painful and debilitating, which may sometimes lead to serious complications and can significantly impact the quality of life for patients.

The MAA submission was supported by Phase 3 clinical studies, GEMINI I, GEMINI II, GEMINI III and GEMINI LTS (Long-term Safety), which are part of the GEMINI Studies™, a four-study clinical research program to investigate the efficacy and safety of vedolizumab on clinical response and remission
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
2. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
3. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
4. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
5. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
6. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
7. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
8. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
9. Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
10. Bayer Submits New Drug Application for Riociguat for the Treatment of Pulmonary Arterial Hypertension and Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
11. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014  Synthetic Biologics, Inc. (NYSE MKT: ... candidates targeting specific pathogens that cause serious infections and ... market activity in the Company,s stock, the NYSE MKT ... its usual practice. The Company stated that its policy ... About Synthetic Biologics, Inc. Synthetic Biologics, ...
(Date:7/29/2014)... , July 29, 2014 New high priced ... Part D by a projected $2.9 to $5.8 billion ... actuarial firm Milliman released today by the Pharmaceutical Care ... premiums could increase by as much as 8.6 percent ... drugs, including Sovaldi and Olysio. The study ...
(Date:7/29/2014)... ALBANY, New York , July 29, 2014 /PRNewswire/ ... published by Transparency Market Research "Surgical Navigation Systems Market ... Systems) - Global Industry Analysis, Size, Share, Growth, Trends ... systems market was valued at USD 218.5 million in ... of 4.5% from 2014 to 2020, to reach an ...
Breaking Medicine Technology:Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 4
... , DUBLIN, Ohio, Dec. 2 Cardinal Health today announced ... directors, effective immediately. , Cox, 52, most recently served as ... Corp. She completed her tenure with the company at the ... Prior to her term at Schering-Plough, Cox served as president ...
... , , ROCKVILLE, Md., Dec. 2 ... results from the first stage of a two-stage pivotal Phase ... 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine. Novavax ... Mexico to support registration of the vaccine in Mexico and ...
Cached Medicine Technology:Cardinal Health Names Carrie Cox to Board of Directors 2NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 2NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 3NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 4
(Date:7/29/2014)... Florida (PRWEB) July 29, 2014 Child abuse ... for law students this week. The scholarship will help future ... children and their families. , Steinger, Iscoe and Greene lawyers ... and want tomorrow’s attorneys to do the same. More than ... year according to the nonprofit Childhelp (retrieved 7/22/2014). ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 As testosterone ... U.S. courts, Bernstein Liebhard LLP notes that a new ... men with Type 2 diabetes. The research, which was ... Metabolism on June 30th, involved 88 men who suffered ... to moderate aging male symptoms and erectile dysfunction. Roughly ...
(Date:7/29/2014)... Gerontological Society of America (GSA) the nation,s ... has chosen Barbara J. Bowers, PhD, RN, FAAN, ... of the Task Force on Minority Issues in Gerontology ... annually to an individual who has exemplified outstanding commitment ... of aging. , The award presentation will take place ...
(Date:7/29/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... N. Gitlin, PhD, of the Johns Hopkins University Schools ... the M. Powell Lawton Award. , This distinguished ... led to an innovation in gerontological treatment, practice or ... public policy change that has led to some practical ...
(Date:7/29/2014)... 29, 2014 Outsourced coding and ... in the number of hospitals contracting for external ... deadline, according to the recently published Black Book™ ... found in the reports “Top Ranked Clinical Documentation ... outsource Clinical documentation audit, review and programming. By ...
Breaking Medicine News(10 mins):Health News:Steinger, Iscoe & Greene Offers Child Advocate Scholarship 2Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 2Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 3Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 4Health News:Bowers to receive GSA's 2014 Minority Mentorship Award 2Health News:Gitlin earns GSA's 2014 M. Powell Lawton Award 2Health News:Clinical Documentation Improvement Heats Up as Half of US Hospitals Make 2015 Preparations for ICD-10, the Rest to Rely on Outsourcers, Black Book Survey Reveals 2Health News:Clinical Documentation Improvement Heats Up as Half of US Hospitals Make 2015 Preparations for ICD-10, the Rest to Rely on Outsourcers, Black Book Survey Reveals 3
... Wellness of Irvine Hires Agency for Public Relations, ... announces it now provides public relations support for Next ... Web site mapping and,messaging. St. Conti will provide marketing ... "Next Level Wellness has grown a lot in ...
... study shows that health care providers play a key ... colorectal cancer. The findings suggest that interventions targeting both ... colorectal cancer screening rates, and in particular must take ... and worries that cancer will be discovered. The study ...
... 10, 2008) Unlike the rest of the cells in ... dates back to the time when mammals began to evolve. ... cells that contain nuclei that are inactive. Losing the nucleus ... thus enabling more oxygen to be transported in the blood ...
... that helps guide immune cells to the gut has been ... begins its assault on the body,s immune system, according to ... (NIAID), part of the National Institutes of Health (NIH). ... up new avenues of investigation that may help further elucidate ...
... parents urged to turn down the volume on personal music ... in eight -- or about 5 million -- American youngsters ... American Academy of Audiology. , The academy has launched a ... boost awareness of the problem and explain how it can ...
... Allied Healthcare Products,Inc. (Nasdaq: AHPI ) reported today ... fell almost 98 percent from $293,000 last year,or 4 cents ... zero cents,per share., For the first half of the ... percent, from about $495,000 last year, or six cents,per share, ...
Cached Medicine News:Health News:St. Conti Communications to Help Adjust Chiropractor Messaging and Communications 2Health News:Provider influence and patient barriers affect use of colorectal cancer screening 2Health News:How red blood cells nuke their nuclei 2Health News:NIAID scientists identify new cellular receptor for HIV 2Health News:Campaign Targets Noise-Induced Hearing Loss in Kids 2Health News:Allied Healthcare's Net Suffers on Flat Sales, Performance Issues 2Health News:Allied Healthcare's Net Suffers on Flat Sales, Performance Issues 3Health News:Allied Healthcare's Net Suffers on Flat Sales, Performance Issues 4Health News:Allied Healthcare's Net Suffers on Flat Sales, Performance Issues 5
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
Medicine Products: